Tackling the toughest challenges in medicine with the aspiration to cure human diseases.

Leveraging our CRISPRomics^® platform to discover the genome’s top therapeutic targets with curative potential.

Advancing our pipeline of CRISPR/Cas9-engineered Tumor Infiltrating Lymphocytes (eTIL^®) programs and our partnered first-in-class candidates for the treatment of cancer.